arrow
J

Jana de Boniface

capio st gorans hospital
H指数:32
被引数:3,597

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Glucocorticoid prophylaxis influences the systemic immune macroenvironment in patients with early stage, treatment naïve, HER2+ breast cancer

糖皮质激素预防对早期、治疗初治、HER2阳性乳腺癌患者的全身免疫宏观环境的影响

2026-08-250
OA
Association between shoulder joint radiation dose and arm morbidity in the randomized breast cancer trial SENOMAC

肩关节辐射剂量与手臂发病率之间的关联:来自随机乳腺癌试验SENOMAC的研究

2026-02-210
OAAI
A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials

新辅助系统性乳腺癌治疗试验中局部区域治疗报告的核心结局指标集

2025-10-280
OA
Local management of second breast cancer event after primary breast conserving therapy: The patient’s perspective

原发性保乳治疗后第二乳腺癌事件的局部管理:患者的视角

2025-09-270
PRE
Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study

乳腺癌新辅助治疗后低体积淋巴结受累患者的腋窝清扫术:多中心AXSANA队列研究

2025-09-010
PRE
Corrigendum to “Artificial intelligence in breast cancer radiotherapy: Insights from the Toolbox Consortium Delphi study” [The Breast, Volume 83 (2025) 104537]

勘误:“人工智能在乳腺癌放射治疗中的应用:‘工具箱’联盟专家咨询研究”的见解 [The Breast, Volume 83 (2025) 104537]

2025-08-190
PREAI
What guides regional nodal irradiation in node positive breast cancer following upfront sentinel lymph node biopsy?

什么指导着在先行哨兵淋巴结活检后,淋巴结阳性乳腺癌的区域淋巴结放射治疗?

2025-07-200
PRE
Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – Results from the prospective AXSANA registry trial

新辅助化疗后腋窝超声的诊断性能——来自前瞻性AXSANA登记研究的结果

2025-07-050
PRE
Lost axillary markers after neoadjuvant chemotherapy in breast cancer patients - data from the prospective international AXSANA (EUBREAST 3) cohort study (NCT04373655)

新辅助化疗后乳腺癌症患者腋窝标记物丢失——来自前瞻性国际AXSANA(EUBREAST 3)队列研究(NCT04373655)的数据

2025-06-250
OA
Radar reflectors for marking of target lymph nodes in initially node-positive patients receiving neoadjuvant chemotherapy for breast cancer-a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial
2025-02-200
PRE